EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
about
Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancerSecond-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancerIntegrating diet and exercise into care of prostate cancer patients on androgen deprivation therapyThe Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other CancersMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantIs extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literatureHyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissueSalvage radiotherapy after radical prostatectomy: prediction of biochemical outcomesAntagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancerThe RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7Ultrasound- and MR-guided focused ultrasound surgery for prostate cancer.Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceCommunity-based recreational football: a novel approach to promote physical activity and quality of life in prostate cancer survivors.Usefulness of ultra-sensitive prostate-specific antigen following radical prostatectomy.Changes of protein expression in prostate cancer having lost its androgen sensitivity.Clinical predictor of survival following docetaxel-based chemotherapy.Drivers for change in the management of prostate cancer - guidelines and new treatment techniques.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic reviewHypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review)Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.Metabolic effects of androgen deprivation therapyIdentification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol for the 'FC Prostate' randomized controlled trialA switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancerSurveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialRadiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cellsThe TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancerRadium-223 for the treatment of castration-resistant prostate cancer.Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancerToremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trialClinical significance of free-to-total prostate-specific antigen (PSA) ratio in advanced prostate cancer patients with PSA less than 0.1 ng/ml after hormone treatment
P2860
Q24192969-4BF8D530-8B8E-49EC-9693-D7C2B1C268E3Q24201772-D7192724-E1ED-4E8C-8E52-691030EF169DQ26738281-BABA927E-1BA2-451C-9746-1F9AB5D0B720Q26740401-D92DA8E7-6F45-4753-85B4-EAA7BAFCBECCQ26851177-5C30FA8E-E3DF-4B9B-8FBB-57FAC5797DE9Q28075601-F8E21104-084F-4621-B13A-2454A624DC3DQ28298900-9F58A3B5-3BF5-46D4-B3DD-CF97F27F3D5AQ28541306-AA42A7D6-9918-4538-B7C3-769ADFA9DE98Q30360857-C0930268-E094-4659-995C-5D94DA6F2131Q30370955-0AC7318F-F681-4959-9E72-5FDB45DDD92AQ30465892-550A6328-4B00-43D3-990F-343F968E2D75Q30976248-0E0CA788-1848-4033-A88E-0FD5CDA94F9AQ33648490-66EE1086-9A60-444E-B5A4-9D27B0EE056AQ33775723-6C580405-07EC-42E7-A964-F2911EEA40D0Q33789117-90AE5A26-3814-4114-927F-A476C0627898Q33833780-84CEB591-FB4F-474E-A5E7-7377F94D45F0Q33932975-266B3067-0370-41CF-BE18-2B4C7E71036DQ34043941-74DD0497-46BE-4014-AD70-33622E56CC2CQ34141580-832D23C0-CB7D-4C45-B219-1C0FE7620725Q34294112-4AC38725-3660-4CC0-A1C5-C4A9625639FBQ34294888-ED331B68-72E3-4E6E-A2F2-3B3F7C936550Q34296202-A55BFA79-5E8A-4CE7-BE21-9AA9E51B05F1Q34344798-8E4F2BC4-E4C4-4E47-9BEB-8D1495AD19FEQ34375823-5D4892C5-01F8-41B6-94B7-7FE12F57A1CDQ34432859-BEA0F894-DA44-4DAD-8128-76FEDDE41E37Q34481621-C14B0648-2AB9-46CE-B790-76E2F61CF9EAQ34627540-8DB49D85-A489-4298-B76D-DEEB9227C105Q34951665-EB6D4E95-9A7E-49E3-9A4D-7D66FA445493Q34962416-F3E7D530-4437-46ED-80C4-855540CE0A43Q34993890-6D26D921-CE73-48BA-9E1A-AC11B99BFF66Q35065300-78AC069E-BDB7-48DF-92B6-F8A2749AA753Q35176048-3BECA947-67BE-42FD-8240-EC7CB103B10BQ35253783-77BC4BB6-A771-4D39-880B-D62E3CDCDA4DQ35579329-7EEE546C-90B2-47D3-B492-E9956560EA43Q35582540-A3513D91-FBC2-4FEC-B7A7-97F20210C3D6Q35653986-24DC8287-7658-4F77-82AE-97F9BC4B0E47Q35742655-500E4C30-9EC3-4E46-904E-4D21D4B1C146Q35828584-45E3D23D-C253-4E57-8899-F57E1675BB72Q35829785-141091D5-CA6F-46FA-9A96-3A7209D9A73FQ35851975-2A80640A-5C17-4747-A12E-891CABB0C5A5
P2860
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@en
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@nl
type
label
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@en
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@nl
prefLabel
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@en
EAU guidelines on prostate can ...... ion-resistant prostate cancer.
@nl
P2093
P1433
P1476
EAU guidelines on prostate can ...... tion-resistant prostate cancer
@en
P2093
Axel Heidenreich
Filiberto Zattoni
Hans-Peter Schmid
Joaquim Bellmunt
Malcolm Mason
Michel Bolla
Nicolas Mottet
Thomas Wiegel
Vsevolod Matveev
P304
P356
10.1016/J.EURURO.2011.01.025
P407
P577
2011-01-25T00:00:00Z